Sign up USA
Proactive Investors - Run By Investors For Investors

Ventripoint increases placement to C$3.2mln

VentriPoint Diagnostics shares shot up by a fifth on Wednesday after the company said it is increasing the maximum gross proceeds of its non-brokered private placement to C$3.2mln from C$2mln and will now issue up to 10 million units at 32 cents per unit
Ventripoint increases placement to C$3.2mln
Private placement proceeds upped to C$3.2mln

VentriPoint Diagnostics (CVE:VPT) shares shot up by a fifth on Wednesday after the company said it is increasing the maximum gross proceeds of its non-brokered private placement to C$3.2mln from C$2mln and will now issue up to 10 million units at 32 cents per unit.

Read: VentriPoint arranges C$2mln placement

WATCH: 'We have a shot at a multi-billion dollar company' ...

Each unit consists of one common share of Ventripoint and one common share warrant. Each warrant will entitle the holder thereof to acquire one common share at a price of 50 cents per common share for a period of two years after the issuance of the warrant.

The corporation is also announcing the private placement is oversubscribed and no further orders will be accepted. The corporation expects to close the private placement on or before March 21, 2017.

The corporation also announces that it has expressions of interest to enter into agreements with holders of debentures previously issued by the corporation to issue an additional 1,915,625 units to the holders of the debentures as payment in full of $613,000, being the aggregate of all amounts due under the debentures, as a share-for-debt transaction. Should all debenture holders complete the transactions, the corporation would be debt free. One insider of the corporation, Dr. George Adams, would be issued 312,500 units for his $100,000 debenture.

VentriPoint shares were up 18% at C$0.46 on Wednesday.

View full VPT profile View Profile

VentriPoint Diagnostics Timeline

Newswire
March 10 2017

Related Articles

1-Operation.jpg
January 18 2017
Deltex’s overseas sales are booming but its previously dominant NHS revenues are dropping off
the word antioxidant
August 15 2017
The heparin test is the firm’s lead product; however the company’s OxiChek device for oxidative stress is also gaining traction
pregnant woman sitting in park
June 13 2017
The £225,000 order is from HuanZhong Biotech, Concepta’s partner in China
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use